189 related articles for article (PubMed ID: 2502913)
1. Fibrinogenolysis in thrombotic thrombocytopenic purpura.
Kakishita E; Koyama T; Higuchi M; Kunitomi O; Oura Y; Nagai K
Am J Hematol; 1989 Sep; 32(1):14-9. PubMed ID: 2502913
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
Watanabe R; Wada H; Miura Y; Murata Y; Watanabe Y; Sakakura M; Okugawa Y; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Shiku H; Nobori T
Clin Appl Thromb Hemost; 2001 Jul; 7(3):229-33. PubMed ID: 11441985
[TBL] [Abstract][Full Text] [Related]
3. Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation.
Fukao H; Ueshima S; Okada K; Yamamoto K; Matsuo T; Matsuo O
Thromb Res; 1992 Oct; 68(1):57-65. PubMed ID: 1280377
[TBL] [Abstract][Full Text] [Related]
4. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura.
Wada H; Kaneko T; Ohiwa M; Tanigawa M; Hayashi T; Tamaki S; Minami N; Deguchi K; Suzuki K; Nakano T
Am J Hematol; 1993 Oct; 44(2):101-5. PubMed ID: 8266913
[TBL] [Abstract][Full Text] [Related]
5. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
6. [Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome].
Fukao H; Yamamoto K; Matsuo O
Rinsho Byori; 1991 Jul; 39(7):720-6. PubMed ID: 1920864
[TBL] [Abstract][Full Text] [Related]
7. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.
Sakata Y; Murakami T; Noro A; Mori K; Matsuda M
Blood; 1991 May; 77(9):1949-57. PubMed ID: 1708294
[TBL] [Abstract][Full Text] [Related]
8. Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura.
Glas-Greenwalt P; Hall JM; Panke TW; Kant KS; Allen CM; Pollak VE
J Lab Clin Med; 1986 Nov; 108(5):415-22. PubMed ID: 2430036
[TBL] [Abstract][Full Text] [Related]
9. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Paloma MJ; Páramo JA; Rocha E
Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor activity in bacterial infection.
Páramo JA; Fernández Diaz FJ; Rocha E
Thromb Haemost; 1988 Jun; 59(3):451-4. PubMed ID: 3142082
[TBL] [Abstract][Full Text] [Related]
11. Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney.
Xu Y; Hagege J; Mougenot B; Sraer JD; Rønne E; Rondeau E
Kidney Int; 1996 Dec; 50(6):2011-9. PubMed ID: 8943484
[TBL] [Abstract][Full Text] [Related]
12. Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
Velasco F; Torres A; Rojas R; Alvarez MA; Gomez P; Castillo D
Haemostasis; 1992; 22(3):117-23. PubMed ID: 1427455
[TBL] [Abstract][Full Text] [Related]
13. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
[TBL] [Abstract][Full Text] [Related]
14. The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.
Falkon L; Garí M; Borrell M; Fontcuberta J
Blood Coagul Fibrinolysis; 1992 Feb; 3(1):33-8. PubMed ID: 1623118
[TBL] [Abstract][Full Text] [Related]
15. Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation.
Asakura H; Jokaji H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
Am J Hematol; 1991 Mar; 36(3):176-83. PubMed ID: 1899963
[TBL] [Abstract][Full Text] [Related]
16. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M
Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036
[TBL] [Abstract][Full Text] [Related]
17. An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation.
Asakura H; Ontachi Y; Mizutani T; Kato M; Saito M; Kumabashiri I; Morishita E; Yamazaki M; Aoshima K; Nakao S
Crit Care Med; 2001 Jun; 29(6):1164-8. PubMed ID: 11395595
[TBL] [Abstract][Full Text] [Related]
18. [Changes in molecular markers in patients with thrombotic thrombocytopenic purpura].
Takamatsu J
Nihon Rinsho; 1993 Jan; 51(1):135-7. PubMed ID: 8433505
[TBL] [Abstract][Full Text] [Related]
19. Production of proteases type plasminogen activator and their inhibitor in cornea.
Mirshahi M; Mirshahi S; Soria C; Soria J; Thomaidis A; Pouliquen Y; Faure JP
Biochem Biophys Res Commun; 1989 May; 160(3):1021-5. PubMed ID: 2499321
[TBL] [Abstract][Full Text] [Related]
20. Characteristics Behaviors of Coagulation and Fibrinolysis Markers in Acquired Thrombotic Thrombocytopenic Purpura.
Sakai K; Wada H; Nakatsuka Y; Kubo M; Hayakawa M; Matsumoto M
J Intensive Care Med; 2021 Apr; 36(4):436-442. PubMed ID: 31964209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
